Disease Doesn’t Recognize State Lines
Mycoplasma bovis can be a problem for any operation.
October 28, 2010 — The line between states and counties doesn’t mean a thing to disease — especially when talking about particularly costly challenges like Mycoplasma bovis. If there are cattle in the area, then producers should be concerned about the bacteria and disease related to M. bovis.
“Studies show that presence of M. bovis goes from below 5 percent at arrival in feedlots and backgrounding operations to 70 to 80 percent in the first three to four weeks,” says Daniel Scruggs, DVM, Veterinary Operations, Pfizer Animal Health. “M. bovis is one of the most commonly isolated organisms from cattle and often fails to respond to respiratory treatment, but its presence doesn’t always result in disease. Even though the factors that lead to disease yet to be determined, M. bovis is still extremely frequent. If commingled cattle are part of an operation, then M. bovis probably is as well.”
One of the most common infectious agents connected to clinical cases of bovine respiratory disease (BRD), M. bovis often leads to joint infections, ear infections,1 weight loss, pneumonia and fever.2 However, once clinical signs are obvious, it’s often too late to treat it effectively, regardless of what you use, Dr. Scruggs says.
“Once you see signs of M. bovis-related disease, your ship for meaningful intervention has already sailed,” he says. “Early in the course of BRD, there’s no way to tell with confidence if you’re dealing with M. bovis, Mannheimia haemolytica or Pasteurella multocida. Studies show that M. bovis is a player early in the disease process, so it makes sense to use control and treatment programs shown to be effective on M. bovis in newly arrived cattle.”
Dr. Scruggs says producers should pay close attention to classes of cattle that are most likely to develop M. bovis-related disease, including cattle that have been commingled, small cattle, and cattle that have been nutritionally stressed or were particularly stressed when received.
“If producers suspect M. bovis-related disease, they should consult their veterinarians for proper diagnosis and treatment options,” Dr. Scruggs says. “And, they should consider using an antimicrobial that is labeled for both treatment and control of M. bovis.”
DRAXXIN® (tulathromycin) Injectable Solution is the only antimicrobial labeled for treatment and control of BRD due to M. bovis — and one treatment can be effective for up to 14 days. In one study, 85 percent of cattle were treated successfully after a single injection with virtually no difference in mortality rates or average daily gain.3
“Control of M. bovis is very important,” Dr. Scruggs says. “You don’t ever want to be in a salvage situation.”
Important Safety Information: Do not use DRAXXIN in calves to be processed for veal. A pre-slaughter withdrawal time has not been determined for pre-ruminating calves. Effects on reproductive performance, pregnancy and lactation have not been determined. DRAXXIN has a pre-slaughter withdrawal time of 18 days.
For more information, contact:
Pfizer Animal Health
1Dyer NW. Recommendations on control of Mycoplasma bovis infection in beef feedlots. North Dakota State University 2008 Beef Research Report.
2Bilderback M. Mycoplasma pneumonia-arthritis syndrome in stocker calves. Off the Hoof, March 2010;6-8.
3Pfizer Animal Health Technical Bulletin. Efficacy of DRAXXIN, followed by 7-, 10-, or 14-day post-treatment intervals against naturally occurring bovine respiratory disease. August 2006.
All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2010 Pfizer Inc. All rights reserved. DRX10016.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States